Tag: BriaCell Therapeutics Corp.
August 17, 2020
BriaCell Presents Clinical and Scientific Findings at the Annual Symposium of Society of Surgical Oncology 2020
Preliminary safety and efficacy data are being presented today from the clinical trials of Bria-IMT™ in combination with immune checkpoint...
May 14, 2020
BriaCell Announces Presentation and Abstract Publication at 2020 American Society of Clinical Oncology (ASCO) Meeting
New data and pathological findings on BriaCell’s lead candidate, Bria-IMT™, to be Highlighted at ASCO 2020 in a Poster Presentation
May 12, 2020
BriaCell Continues Business and Clinical Operations During COVID-19 Pandemic
BriaCell Therapeutics announces that the Phase I/IIa clinical study of Bria-IMT™, for breast cancer treatment, with Incyte Corporation’s immune checkpoint...
April 27, 2020
BriaCell Files Patent Application for Novel Therapeutics for Cancer
BriaCell Therapeutics (TSXV:BCT) has filed a provisional patent application with the USPTO outlining the development and use of novel therapeutics
April 21, 2020
BriaCell Files New Provisional Patent Application for Antibody-Based Treatment of Infectious Diseases
BriaCell Therapeutics (TSXV:BCT) has filed a provisional patent application with the USPTO outlining the development and use of certain antibodies...
April 14, 2020
BriaCell Files Coronavirus Immunotherapy Patent
BriaCell Therapeutics (TSXV:BCT) announces that it has filed a provisional patent application with the USPTO.
March 31, 2020